What is King Pharmaceuticals's allowance for credit losses?

King Pharmaceuticals (KG) reported allowance for credit losses of $0 in Q1 2026.

What does allowance for credit losses mean?

Reserve held against the loan portfolio for estimated future credit losses under the CECL methodology — a contra-asset reducing net loans.

King Pharmaceuticals KG Allowance for credit losses

Allowance for credit losses at other companies

KKR & Co.KKR

$717.95M+16.0%

Universal Insurance HoldingsUVE

$816K-1.6%

Kearny FinancialKRNY

$44.72M+0.6%

Arch Capital GroupACGL

——

Reinsurance Group of AmericaRGA

——

W.R. BerkleyWRB

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's allowance for credit losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's allowance for credit losses?: King Pharmaceuticals (KG) reported allowance for credit losses of $0 in Q1 2026.
What does allowance for credit losses mean?: Reserve held against the loan portfolio for estimated future credit losses under the CECL methodology — a contra-asset reducing net loans.